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Prosthetic aortic valve replacement in the small aortic root raises concerns 
of its long-term effects. Between 1978 and 1994, 270 patients received only 
small aortic prostheses (<21 mm). There were 117 men (43.3%) and 153 
women (56.7%) with a mean age of 64.3 - 11.6 years (range 19 to 87 years). 
The body surface areas ranged from 1.2 to 2.26  m 2 (mean 1.71 4--- 0.27 mE). 
Ninety-one percent of patients had New York Heart Association class II I  or 
IV symptoms and 33% underwent concomitant coronary artery bypass 
grafting. The operative mortality rate was 3.3% (9 deaths) and follow-up 
(100%) extended from 1 to 16 years (mean 6.2 - 3.9 years) with cumulative 
survival of 1676 patient-years. There were 55 late deaths (3.28% per 
patient-year). The linearized rates of morbidity reported as percent per 
patient-year were as follows: structural failure, 0%; paravalvular leak, 
0.12%; prosthetic endocarditis, 0.24%; anticoagulant-related morbidity, 
1.24%; and thromboembolism, 1.10%. In 89% of the survivors New York 
Heart Association functional performance had improved to class II or I. 
The actuarial survival with 95% confidence intervals at 5, 10, and 16 years 
was 86.9% (82.5%, 91.3%), 68.6% (60.6%, 76.6%), and 53.6% (36.6%, 70.6%), 
respectively. Freedom from late valve-related vents (95% confidence intervals) 
at 10 and 16 years was as follows: thromboembolism, 91.2% (86.6%, 95.8%) and 
78.3% (62.6%, 94%); anticoagulant-related morbidity, 89.1% (83.8%, 94.4%) 
and 81.0% (65.1%, 96.9%); and prosthetic endocarditis, 98.8% (97.5%, 100%) 
and 98.8% (97.5%, 100%), respectively. Multivariate analysis revealed age at 
operation, myocardial infarction, and endocarditis affected the long-term 
survival. The risk of sudden death irrespective of body surface area and valve 
size was not statistically different. Thus the long-term performance of the St. 
Jude Medical valve in small aortic roots is satisfactory. (J Thorac Cardiovasc 
Surg 1997;113:499-509) 
T he use of an aortic valve prosthesi  in the small anulus raises a concern about harmful effects of 
residual obstruction to the left ventricular outflow 
tract, which may cause significant hemodynamic 
limitations. Since June o f  1978 at Rhode Island 
Hospital, small sizes of St. Jude Medical aortic 
prostheses (19 mm and 21 mm) have been used 
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without aortic root enlargement. We believe the 
good hemodynamic quality of this prosthesis justi- 
fies its use in the native small aortic anulus. 
Excellent hemodynamic performance of the St. 
Jude Medical mechanical prosthesis has been re- 
ported by many investigators. 1-3 St. Jude Medical 
mechanical prostheses in izes 19 mm and 21 mm 
are designed and demonstrated in in vitro studies to 
have a resting gradient of 6 mm Hg and peak 
gradient of less than 15 mm Hg? '4 Kratz and 
associates s reported good results in patients with a 
body surface area (BSA) less than 1.9 m 2 with the 
use of 19 mm and 21 mm St. Jude Medical prosthe- 
ses, but reported an increased incidence of late 
sudden death among those with a BSA less than 
1.9 m 2. This study reports our experience with 19 
mm and 21 mm St. Jude Medical prostheses in 
patients with a small aortic root and attempts to 
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Fig. 1. Preoperative and follow-up NYHA functional class presentation. Pts, Patients. 
investigate the risk factors for long-term morbidity 
and mortality, particularly as related to valve size 
and large BSA. 
Material and methods 
Between June 1978 and June 1994, 593 adult patients 
underwent aortic valve replacement with the St. Jude 
Medical mechanical prosthesis. Among these were 327 
patients (55%) who received a small prosthesis (-<21 
mm). Patients with double valve replacement were ex- 
cluded from the study. Two hundred seventy (46%) 
patients received small aortic valves only (17 ram, 1 
patient; 19 mm, 79; 21 mm, 190). There were 117 men 
(43.3%) and 153 women (56.7%) between the ages of 19 
and 87 years with a mean age of 64.3 _+ 11.6 years. The 
BSAs ranged from 1.20 to 2.26 m 2 (mean 1.71 + 0.27 m2). 
Thirty-four patients (13%) had had previous cardiac 
operations. Ninety patients (33%) underwent a concomi- 
tant coronary artery bypass grafting (CABG) procedure. 
Preoperative New York Heart Association (NYHA) class 
presentations were as follows: NYHA class II, 24 patients; 
NYHA class III, 162 patients; and NYHA class IV, 84 
patients (91% in NYHA class III or IV). Two hundred 
eighteen patients (81%) underwent operation electively, 
whereas operation was done urgently in 40 patients and 
on an emergency basis in 12 patients. 
Operative technique. Before 1987, moderate hypother- 
mic (25 ° to 28 ° C) cardiopulmonary bypass was used 
including bicaval cannulation with snares and a membrane 
oxygenator. The left ventricle was vented via the right 
superior pulmonary vein. Myocardial protection was 
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Table I. Freedom from late events 
5 D" 10 D 16 Yr 
Events Estimate (%) 95% CI (%) Estimate (%) 95% CI (%) Estimate (%) 95% CI (%) 
Late death 86.9 82.5, 81.3 
Cardiac death 95.3 92.6, 98 
Thromboembolism 94.8 91.8, 97.8 
Anticoagulation-related h morrhage 94.3 91.4, 97.2 
Valve-related reoperation 98.8 97.5, 100 
Prosthetic endocarditis 98.8 97.5, 100 
Paravalvular leak 99.6 98.8, 100 
Valve-related complications 85.5 81, 90 
68.6 60.6, 74.6 53.6 36.6, 70.6 
85.6 70.9, 92.3 94.9 54.4, 95.4 
91.2 86.6, 95.8 78.3 62.6, 94 
89.1 83.8, 94.4 81 65.1, 96.9 
98.8 97.5, 100 98.8 97.5, 100 
98.8 97.5, 100 98.8 97.5, 100 
98.9 97.3, 100 98.9 97.3, 100 
79.9 63.2, 78.6 56.7 41.7, 71.7 
achieved with the use of cold crystalloid cardioplegia 
followed by multidose cold blood cardioplegia. Topical 
myocardial cooling was done with ice-cold saline slush. 
After 1987, we routinely used normothermic (37 ° C) car- 
diopulmonary bypass. ~The technique of myocardial pro- 
tection remained unchanged uring the entire period. The 
aortic anulus was debrided meticulously and measured 
with a snugly fitting sizer. The St. Jude Medical valve 
prosthesis was implanted intraannularly with use of evert- 
ing interrupted and pledget-supported ransverse mattress 
sutures. One hundred sixty-six patients (61%) had pure 
aortic stenosis, 10 patients (4%) pure aortic regurgitation, 
and 94 patients (35%) a mixed aortic lesion. Pathologic 
features of the explanted valves studied in our series were 
as follows: bicuspid in 204 patients (76%), rheumatic valve 
disease in 44 patients (16%), myxomatous degeneration i  
10 patients (4%), and infective in 12 patients (4%). 
Anticoagulation. All patients received anticoagutation 
therapy with warfarin beginning on postoperative day 2. 
We used prothrombin time to guide the dosage of warfa- 
rin before 1992. Before 1985 prothrombin time was kept 
between 2 and 2.5 times the control value and during the 
period from 1985 to 1992 it was kept between 1.5 and 2 
times the control value. Since 1992 we have been using the 
international normalized ratio as control and kept the 
value between 3.0 and 3.5. All patients ince 1992 have 
been followed up to receive a warfarin dosage to keep the 
international normalized ratio in the range of 3.0 to 3.5. 
Follow-up. All patients were followed up annually 
(100% follow-up) by their referring physician or cardiol- 
ogist. Follow-up information was obtained from these 
sources. We contacted all the surviving patients again by 
telephone during the fall of 1995. They were questioned 
by a trained person with a standard questionnaire. All 
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Fig. 3. Kaplan-Meier actuarial survival curve for late death. Dotted lines represent the 95% CIs. 
hospital records for patient admissions were analyzed to 
enumerate valve-related problems. Follow-up ranged 
from 1 year to 16 years. Mean follow-up was 6.2 -+ 3.9 
years and cumulative patient survival was 1676 patient- 
years (pt-yrs). Mortality and morbidity were stringently 
defined per guidelines published by The Society of Tho- 
racic Surgeons and The American Association for Tho- 
racic Surgery. 7All data were stored in a Fox-pro database 
specially written for our use. 
Stat is t ica l  analys is .  Statistical analyses were done with 
the SAS statistical software package. Discrete variables 
are presented as counts and percentages. Continuous 
variables are presented as mean plus or minus the stan- 
dard deviation. Late events were also calculated as linear- 
ized rates (number of events divided by years at risk) and 
presented as percent per patient-year. Statistical signifi- 
cance (p value) was at the nominal evel of 0.05. 
The Kaplan-Meier product limit method was used to 
calculate the freedom from an event, s The number of 
patients at risk for an interval is shown in the graphs, 
along with the 95% confidence limits for the estimates. 
Variables considered to be risk factors (NYHA class at 
implantation, BSA, CABG, age at operation, and preim- 
plantation valve pathologic ondition) were examined by 
the Kaplan-Meier product limit method, and the stratified 
log-rank test was used to determine statistical significance. 
A Cox proportional hazard model with time-dependent 
covariates 9 was done to determine the model that best 
predicted time to mortality. The importance of the covari- 
ates was evaluated singly and in combination by stepwise 
procedures. The model that best fit the data included age 
at implantation and the events endocarditis and myocar- 
dial infarction. 
Resu l ts  
Operat ive  mortality. The overall operative mor- 
tality rate was 3.3% (9 patients). Among the 34 
patients who underwent a second operation there 
were 2 deaths for a reoperation mortality rate of 
5.9%. There were 4 deaths (mortality rate 4.5%) in 
90 patients who had undergone concomitant CABG. 
Mortality according to NYHA functional class 
showed no operative deaths among 24 patients in 
NYHA class II, 3 deaths in 162 patients in NYHA 
class I I I  (mortality rate 1.9%), and 6 deaths in 84 
patients in NYHA class IV (mortality rate 7%). 
Functional class. All patients were assessed for 
functional performance by NYHA classification 
during follow-up. Fig. 1 shows the preoperative and 
follow-up presentations. Survival curves by the func- 
tional class are shown in Fig. 2. Survival according to 
the NYHA class was not statistically significant (p 
value = 0.42). 
Late  mortality. Fifty-five patients died during fol- 
low-up for a linearized rate of late mortality of 
3.3%/pt-yr. There were 32 patients with cardiac- 
related deaths for a linearized rate of 1.9%/pt-yr. 
Among the cardiac deaths, 21 deaths (1.3%/pt-yr) 
were a result of myocardial infarction and 11 deaths 
(0.7%/pt-yr) were from sudden cardiac events. 
Seven patients (0.4%/pt-yr) died as a result of major 
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stroke. The remaining 16 deaths (0.95%/pt-yr) were 
caused by noncardiac auses. Survival statistics with 
freedom from the late events are shown in Table I. 
Actuarial survival (Fig. 3) by the Kaplan-Meier 
method with 95% confidence intervals (CIs) was 
86.9% (82.5%, 91.35%) and 53.6% (36.6%, 70.6%) 
at 5 and 16 years, respectively. 
The influence of age on long-term survival 
showed decreased survival in patients with ages 
older than 70 years. Fig. 4 shows the survival curves 
for patients divided into two age groups: ages 69 
years and younger and 70 years and older. The 
log-rank test showed statistical significance withp = 
0.01. 
Sudden death might be influenced by residual 
outflow obstruction across the prosthetic aortic 
valve. From the published ata for orifice area of St. 
Jude Medical prosthetic valves, the calculated valve 
area index for a patient with a BSA of 1.9 m 2 and an 
implanted 19 mm or 21 mm prosthesis is 0.86 
cm2/m 2 or 1.08 cm2/m 2, respectively. Therefore a 
BSA of 1.9 m 2 or greater was considered a potential 
risk factor for sudden death. The relationship of 
BSA to incidence of late sudden death was studied. 
In this series, a size 19 mm prosthesis was implanted 
in 77 patients with a BSA less than 1.9 m 2 and in 2 
patients with a BSA 1.9 m 2 or greater, and a size 21 
mm prosthesis was implanted in 131 patients with a 
BSA less than 1.9 m 2 and in 56 patients with a BSA 
1.9 m 2 or greater. The variables of a BSA less than 
1.9 m 2 and a BSA 1.9 m 2 or greater as risk factors for 
sudden death were plotted on a survival curve (Fig. 
5). We found no statistical significance by log-rank 
test (p = 0.79) for incidence of sudden death. 
However, when we analyzed influence of preimplan- 
tation valvular lesion on sudden death, sudden 
death significantly increased in patients with pure 
aortic stenosis (p = 0.01). Fig. 6 graphically illus- 
trates this finding. Preimplantation aortic stenosis 
was not statistically significant for all cardiac deaths 
(p = 0.5) or late mortality (p = 0.45). Larger BSA 
had no statistically significant effect on long-term 
survival among patients who received 19 mm or 21 
mm valves, although the number of patients who 
received a size 19 mm prosthesis with a BSA 1.9 m 2 
or greater was small. The relevant survival curves 
are shown in Fig. 7 (p = 0.48). 
The influence of concomitant CABG on late 
mortality was analyzed. Survival at the end of 10 
years for those with CABG and without CABG with 
the 95% CIs was 68.4% (59.3%, 77.5%) and 61.2% 
(45.4%, 77%), respectively, without statistical signif- 
icance (p = 0.84). 
Late morbidity 
Structural deterioration. No patient had structural 
malfunction of the valve in this series. 
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Paravalvular leak. Two patients had a paravalvu- 
lar leak, for a linearized rate of 0.12%/pt-yr. One 
patient had a hemodynamically insignificant jet and 
remains free of symptoms. The other patient under- 
went reoperation with aortic root replacement and 
is alive at 6 years after operation and doing well. 
Freedom from paravalvular leak with the 95% CIs 
at 16 years was 98.9% (97.3%, 100%). 
Thrornboembolism. There were no detected cases 
of valve thrombosis. Eighteen patients had a stroke, 
for a linearized rate of 1.10%/pt-yr. There were 11 
permanent and 7 transient neurologic deficits. No 
other embolic complications were noted. The sur- 
vival statistics are given in Table I. The dosages of 
warfarin and the levels of anticoagulation were 
varied for the different imes: 1978 to 1984, 1985 to 
1992, and after 1992. Statistical analysis showed no 
difference in the incidence of thromboembolism 
(p = 0.25) or anticoagulation-related hemorrhage 
(p = 0.61) during the respective periods. 
Anticoagulation-related hernon'hage. Anticoagula- 
tion-related hemorrhage occurred in 20 patients, 
who required hospitalization and transfusion. No 
patient required surgical intervention. The linear- 
ized rate was 1.24%/pt-yr. Table I shows the survival 
statistics. 
Prosthetic endocarditis. Prosthetic valve endocar- 
ditis occurred in four patients, for a linearized rate 
of 0.24%/pt-yr. Three patients underwent reopera- 
tion, with one death. One patient was treated con- 
servatively and is alive, remaining in NYHA class II. 
The freedom from endocarditis in our series with 
the 95% CIs was 98.8% (97.5%, 100%) at 16 years. 
Reoperation. Three patients underwent reopera- 
tion with one death. The linearized rate for reop- 
eration was 0.18%/pt-yr. Fig. 8 shows freedom from 
all valve-related complications and Table I shows 
the survival statistics. 
Discussion 
Management of the small aortic root is a chal- 
lenge to the surgeon with regard to operative tech- 
nique and selection of the prosthesis. The hemody- 
namic performance of small-sized valve prostheses 
in the native aortic root is of genuine concern, 
especially for patients with a larger BSA. It is feared 
that any significant pressure gradient across the 
prosthetic aortic valve will adversely affect late left 
ventricular performance. The Bj6rk-Shiley tilting 
disc prosthesis is reported to have an exercise gra- 
dient of greater than 40 mm Hg across a 21 mm 
valve, l° Small Hancock porcine prostheses have 
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been reported to have gradients of as high as 125 
mm Hg. 1~ Cohn 12 and Jones 13 and their coworkers 
recommended that a small Hancock porcine valve 
should not be used because of these excessive 
pressure gradients. Many investigators have re- 
ported acceptable pressure gradients across small 
St. Jude Medical prostheses at rest and after exer- 
cise.3, 4, 14 Rahimtoola15 identified an aortic valve 
area index of 0.75 cm2/m 2 or less as severe aortic 
stenosis in patients who did not undergo operation. 
As calculated from the published orifice area of St. 
Jude Medical valve prostheses, aortic valve area 
indexes of 0.86 cma/m 2 and 1.08 cm2/m 2, respec- 
tively, would result when 19 mm or 21 mm prosthe- 
ses were implanted in patients with a BSA of 1.9 m 2. 
These postimplantation aortic valve area index val- 
ues suggest significant residual aortic stenosis and 
lead to the concerns of poor long-term cardiac 
performance. Nevertheless, a moderate improve- 
ment in the left ventricular outflow orifice reduces 
the valve gradient exponentially because the rela- 
tionship of the gradient to valve area is curvilinear. 15 
Long-term improvement in the cardiac performance 
is a major finding of this study, on the basis of 
patients' clinical improvement as judged by NYHA 
class. Many patients did well in the early and late 
postoperative periods even when only moderate 
improvement of severe left ventricular obstruction 
was expected. 
In this series late mortality was 3.3%/pt-yr (55 
patients). The incidences of sudden death and car- 
diac death were low irrespective of the BSA. Among 
the operative survivors with preoperative NYHA 
class III or IV symptoms, 93% patients had im- 
proved postoperative functional class in our series. 
Analysis of survival by NYHA class (Fig. 2) showed 
16-year survival for classes II, III, and IV with the 
95% CIs as 59.9% (34.5%, 85.3%), 52.1% (32.7%, 
7i.5%), and 60.9% (45.3%, 76.5%), respectively. 
This demonstrates good long-term performance and 
overall improvement with use of 19 mm and 21 mm 
St. Jude Medical prostheses without annular en- 
largement. With advanced age the resting cardiac 
output diminishes, hence a small enlargement in 
outflow orifice area results in considerable restora- 
tion of basal circulation and a marked improvement 
in functional class. Because the majority of our 
patients were elderly (average age of 64), this may 
explain the observed vast clinical improvement 
among our patients. 
Kratz and associates 5 found that a BSA of 1.9 m 2 
was an independent risk factor for sudden death, but 
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they did not mention the number of patients at risk 
who received size 19 mm or 21 mm prostheses: In 
our series, of patients with a BSA of 1.9 m 2 or 
greater, two received a size 19 mm prosthesis and 56 
received a size 21 ram. In contrast, we did not find a 
BSA of 1.9 m 2 or greater as a risk factor for adverse 
long-term results. As shown in Figs. 5 and 7, our 
analyses of long-term survival and incidence of 
sudden death demonstrated no significant statistical 
difference between patients with a larger BSA and 
their smaller counterparts. However, as noted in 
Fig. 6 native aortic stenosis did statistically increase 
the incidence of sudden death. 
The operative mortalitY rate in this series was 
3.3%, which is comparable with the findings of 
others.2, 5,16-18 In this series 33% of patients under- 
went concomitant CABG and the actuarial survival 
at 10 years was 68.4% (59.3%, 77.5%) and at 16 
years was 60% (47.2%, 78.8%), which compares well 
with findings of the reported series. Czer 17 and 
Arom 2 and their associates reported 9-year survivals 
at 51% and 75.5%, respectively, with a high propor- 
tion of the implanted valves larger than 21 mm. 
Risk factors for long-term survival. In our expe- 
rience long-term survival was affected by advanced 
age at operation and postimplantation events of 
endocarditis and myocardial infarction. The Cox 
proportional hazard model with time-dependent 
covariates howed these events decreased the time 
to mortality (p = 0.003, 0.04, and 0.0001 with risk 
ratios with 95% CIs of 1.04 [1.02, 1.07], 4.69 [3.21, 
25.65], and 9.07 [1.11, 19.92], respectively). Age at 
operation was found to be an independent risk 
factor (age ->70 years increased the late mortality, 
p = 0.01). This study showed survival in two groups, 
patients 69 years and younger and patients 70 years 
and older, with 95% CIs at 10 years, to be 73.7% 
(64.7%, 82.7%) and 53.7% (39.6%, 67.8%), respec- 
tively. Despite overall relative disadvantages of in- 
creased age, the long-term survival of older patients 
remains substantial. Preoperative NYHA class and 
BSA, size of the implant, and concomitant CABG 
did not affect the long-term survival in this series. 
Risk of long-term morbidity. Another principal 
concern of any mechanical valve is its thrombogenic 
potential and the need for anticoagulation. In this 
series there were three periods of different post- 
operative anticoagulation reg!mes with warfarin. 
We did not find any statistical differences in inci- 
dence of thromboembolism and anticoagulation- 
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related hemorrhage between the periods. The re- 
view of Akins 19 of four common mechanical 
prostheses revealed a linearized rate of thromboem- 
bolism of 1.6%/pt-yr (range 0.7% to 2.8%) for the 
St. Jude Medical mechanical prosthesis. Duncan 
and colleagues 2° reported a linearized rate of 
0.99%/pt-yr for thromboembolism a ong the aortic 
valves and freedom from thromboembolism at 5 
years as 97.6% (prothrombin time 1.5 to 2 times the 
control value) and found anticoagulation-related 
complications to be 1.13%/pt-yr, with one patient 
dying as a result of intracranial hemorrhage. Our 
results compare well with those of the aforemen- 
tioned series and show no mortality caused by 
anticoagulafion-related h morrhage. Few data exist 
that show the ideal level of anticoagulation to 
minimize both thromboembolic and hemorrhagic 
complications. Kopf and associates 21used a pro- 
thrombin level of 1.3 to 1.5 times the control value 
and found a linearized rate of anticoagu!ation- 
related hemorrhage of 1.3%/pt-yr, which is no dif- 
ferent that in our experience (1.24%/pt-yr). Our 
findings compare well with those of most of the 
reported series. Akins 22 recently suggested use of a 
composite thromboembolism and bleeding index, 
and in our series this turned out to be 2.3%/pt-yr, 
which compares well with that of all available me- 
chanical prostheses. In our series other valve-related 
complications such as paravalvular leak and endo- 
carditis were also comparable with those in reported 
experiences and we did not encounter any incidence 
of structural failure, which confirms the durability of 
the St. Jude Medical prosthesis. 
To avoid obstruction of the left ventricular out- 
flow tract many techniques have been used to en- 
large the anulus to accommodate a larger-sized 
prosthesis. 23-25 This potentially increases the risks of 
injury to the coronary arteries and to the conduction 
bundle and the risk of surgical hemorrhage. David 
and Uden 26 have described new techniques to ac- 
commodate larger-size prostheses with satisfactory 
short-term results; however, long-term results are 
not available yet. Homograft replacement of the 
aortic valve as an isolated procedure or as root 
replacement 27 has an added advantage of freedom 
from anticoagulation. Replacement of the aortic 
valve with pulmonary autograft may even have some 
growth potential. 28 However, these techniques will 
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require special training and experience and are 
presently not widely used. Routine availability of the 
homograft is also a problem. In this series we 
present a standard and reproducible technique with 
commercially available St. Jude Medical prostheses 
with satisfactory long-term results. Valves in the new 
St. Jude Medical HP (high performance) series have 
an effective orifice equivalent to the next larger 
standard valve size. The future routine use of these 
HP valves may further improve the surgical results. 
In conclusion, we present our clinical experience 
with small-size St. Jude Medical valve prostheses in 
patients with a small native aortic anulus. Our initial 
operative mortality and morbidity and long-term 
follow-up outcome confirm the efficacy of these 
valves in this surgical setting. The long-term perfor- 
mance of aortic valve replacement with small St. 
Jude Medical valves (19 mm and 21 mm) without 
annular enlargement is satisfactory as judged by 
improvement in the functional class of patients, 
survival Statistics, durability of the prosthesis, and 
valve-related morbidity comparable to that of other 
sizes. Age at operation greater than 70 years was the 
only independent risk factor affecting survival. Mul- 
tivariate analysis showed age at operation, myocar- 
dial infarction, and endocarditis affected long-term 
survival. BSA greater than 1.9 m 2, preoperative 
functional class, size of prosthesis, and concomitant 
CABG procedure did not influence long-term sur- 
vival. Therefore we conclude that the use of a size 21 
mm or smaller St. Jude Medical prosthesis in a small 
native aortic anulus is a reasonable alternative. The 
effective orifice of the new high-performance St. 
Jude Medical valve is similar to that of the next 
larger standard valve, and it is reasonable to assume 
that the wide use of these valves might improve the 
results further. 
We gratefully acknowledge the assistance of Sharla 
Williamson and Steve Reinart, who provided statistical 
consultations, and Merry Meyers for her assistance in the 
data collection. 
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